Annexin Pharmaceuticals

Annexin Pharmaceuticals is a clinical-stage biotech with a mission to 'empower the body to fight disease' by targeting phosphatidylserine (PS) exposure, a root pathological mechanism. Its lead asset, ANXV, is a recombinant human Annexin A5 protein currently in a Phase 2a proof-of-concept study for Retinal Vein Occlusion (RVO), with preclinical work ongoing in oncology. The company's strategy is to de-risk and optimize the ANXV program's value through clinical validation in RVO before seeking partnerships or licensing deals to expand into larger indications like cancer and cardiovascular diseases.

Proprietary platform based on recombinant human Annexin A5 (ANXV), a protein that binds with high affinity to exposed phosphatidylserine (PS) on stressed cells to inhibit pro-inflammatory, pro-coagulant, and immune-evasive signaling.

ANXV's primary competition in RVO is the entrenched anti-VEGF standard of care, though its causal mechanism is complementary. In PS-targeting for oncology, it faces other modalities (e.g., anti-PS antibodies) but differentiates via its natural protein structure and internalization property for drug delivery. Its first-mover status in clinical PS modulation is both an advantage and a burden of proof.